5:31 PM
 | 
Jan 16, 2013
 |  BC Extra  |  Company News

FDA grants Priority Review to Tarceva sNDA

Astellas Pharma Inc. (Tokyo:4503) said FDA accepted and granted Priority Review to an sNDA for Tarceva erlotinib for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations as detected...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >